We are leaders in


ImmVirX is a clinical stage oncology company developing novel oncolytic viruses to create powerful cancer immunotherapy combinations.

What we are up to

ImmVirX is actively progressing its novel immuno-oncology agents in the clinic, targeting some of the most prevalent cancer types where patients have limited treatment options.

Our novel oncolytic immunotherapy harnesses the power of viruses to preferentially infect and kill cancer cells and induce systemic anti-tumour immune responses.

The proprietary bio-selected RNA viruses target specific receptor proteins highly expressed on a range of cancer cell types, allowing them to selectively enter, replicate in, and destroy tumour cells while creating beneficial changes in the tumour micro-environment, potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.

In this way, our viral candidates are intended to increase the effectiveness of current immunotherapies, primarily immune checkpoint inhibitors and CAR-T cell therapies, in fighting cancers of high unmet need including colorectal, gastric, hepatocellular and ovarian cancer.

In the News

View our recent news stories

Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.

View All Stories

On Twitter

Darren Shafren & Jia (Jenny) Liu presenting early first in human data of our oncolytic virus at #sitc23.

Very encouraged by progress to date, including strong recruitment & clinician interest. Early stability signals in injected lesions & promising induction of inflammatory…

Delighted to welcome the @OneVenturesVC team, including our new Director Dr Jeannie Joughin, to our Newcastle laboratories to discuss & witness the exceptional progress across the clinical, preclinical & manufacture programs since the recent financing in May.

‘Cancer-fighting biotech ImmVirX secures $15m from OneVentures’

More coverage of our Series B Financing from @BusinessNewsAus


Load More